{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:16:26Z","timestamp":1789571786485,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejphar.2019.172661","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T19:01:10Z","timestamp":1568660470000},"page":"172661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis"],"prefix":"10.1016","volume":"863","author":[{"given":"Vasiliki","family":"Venetsanaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zacharoula","family":"Karabouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.172661_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. an expert panel statement","volume":"71","author":"Athyros","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2019.172661_bib2","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1074\/jbc.M510258200","article-title":"The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice","volume":"281","author":"Cariou","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2019.172661_bib3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","article-title":"FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats","volume":"51","author":"Cipriani","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2019.172661_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/jm401873d","article-title":"Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors","volume":"57","author":"D'Amore","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172661_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.dld.2013.10.021","article-title":"The bile acid TGR5 membrane receptor: from basic research to clinical application","volume":"46","author":"Duboc","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejphar.2019.172661_bib6","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/db11-0815","article-title":"Bile acids acutely stimulate insulin secretion of mouse beta-cells via farnesoid X receptor activation and K(ATP) channel inhibition","volume":"61","author":"Dufer","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2019.172661_bib7","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1021\/jm501273r","article-title":"Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands","volume":"57","author":"Festa","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172661_bib8","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2019.172661_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/164_2019_226","article-title":"Obeticholic acid: an update of its pharmacological activities in liver disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172661_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12876-018-0805-z","article-title":"Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial","volume":"18","author":"Friedrich","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ejphar.2019.172661_bib11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1124\/mol.117.111047","article-title":"Effects of farnesoid X receptor activation on arachidonic acid metabolism, NF-kB signaling, and hepatic inflammation","volume":"94","author":"Gai","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172661_bib12","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2019.172661_bib13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.gastro.2013.07.017","article-title":"Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD?","volume":"145","author":"Karpen","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2019.172661_bib14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2019.172661_bib15","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2019.172661_bib16","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1016\/S0618-8278(19)31582-8","article-title":"A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis","volume":"70","author":"Lawitz","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2019.172661_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2019.172661_bib18","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","article-title":"Non-alcoholic fatty liver disease and risk of cardiovascular disease","volume":"65","author":"Lonardo","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2019.172661_bib19","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/MEG.0000000000000429","article-title":"Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a meta-analysis","volume":"27","author":"Madan","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2019.172661_bib20","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","article-title":"Antiatherosclerotic effect of farnesoid X receptor","volume":"296","author":"Mencarelli","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2019.172661_bib21","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1080\/14656566.2016.1225727","article-title":"Emerging and future therapies for nonalcoholic steatohepatitis in adults","volume":"17","author":"Mintziori","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2019.172661_bib22","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1248\/bpb.34.1885","article-title":"Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice","volume":"34","author":"Miyata","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2019.172661_bib23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2019.172661_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2019.172661_bib25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2019.172661_bib26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13531","article-title":"Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD","volume":"38","author":"Nobili","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2019.172661_bib27","doi-asserted-by":"crossref","first-page":"11055","DOI":"10.1074\/jbc.M117.784322","article-title":"Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism","volume":"292","author":"Pathak","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2019.172661_bib28","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172661_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","author":"Pockros","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2019.172661_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29897","article-title":"Nonalcoholic fatty liver disease: is it time for combination treatment and a diabetes-like approach?","volume":"68","author":"Polyzos","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2019.172661_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","article-title":"Leptin in nonalcoholic fatty liver disease: a narrative review","volume":"64","author":"Polyzos","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2019.172661_bib32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2019.172661_bib33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.ejphar.2019.172661_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2019.172661_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/156652409787847191","article-title":"Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines","volume":"72","author":"Polyzos","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ejphar.2019.172661_bib36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","article-title":"Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease","volume":"46","author":"Polyzos","year":"2012","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2019.172661_bib37","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.metabol.2015.12.009","article-title":"Nonalcoholic fatty future disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2019.172661_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.06.017","article-title":"Regenerate: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.ejphar.2019.172661_bib39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1124\/mol.110.064501","article-title":"Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist","volume":"78","author":"Rizzo","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172661_bib40","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1038\/s41598-019-45178-z","article-title":"Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob\/ob mouse model of biopsy-confirmed NASH","volume":"9","author":"Roth","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2019.172661_bib41","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2019.172661_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Tolbol","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2019.172661_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/hep.22668","article-title":"Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation","volume":"48","author":"Wagner","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2019.172661_bib44","doi-asserted-by":"crossref","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2019.172661_bib45","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/S0618-8278(19)30006-4","article-title":"Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2019.172661_bib46","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919306132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919306132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:29:58Z","timestamp":1757975398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919306132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":46,"alternative-id":["S0014299919306132"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172661","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172661"}}